Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AIM ImmunoTech Inc. Director's Dealing 2015

Apr 29, 2015

35334_dirs_2015-04-29_df46a063-0443-4717-8caf-5ddb9ca04a7d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2015-04-28

Reporting Person: CARTER WILLIAM A (Director, CEO, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-04-28 Common Stock P 100000 $0.242 Acquired 1150585 Direct